A new series of polyvalent drugs obtained by joining edaravone with NO-donor moieties is described. All compounds display high antioxidant power together with NO-dependent vasodilator properties. The analysis of a number of molecular descriptors shows that the antioxidant activity, which is tightly linked to the presence of the edaravone substructure, is principally modulated by lipophilicity. These products are potentially useful in the treatment of cardiovascular disorders in which EDRF deficiency and ROS excess are involved.
Edaravone derivatives containing NO-donor functions
CHEGAEV, Konstantin;CENA, Clara;GIORGIS, Marta;ROLANDO, Barbara;TOSCO, Paolo;BERTINARIA, Massimo;FRUTTERO, Roberta;GASCO, Alberto
2009-01-01
Abstract
A new series of polyvalent drugs obtained by joining edaravone with NO-donor moieties is described. All compounds display high antioxidant power together with NO-dependent vasodilator properties. The analysis of a number of molecular descriptors shows that the antioxidant activity, which is tightly linked to the presence of the edaravone substructure, is principally modulated by lipophilicity. These products are potentially useful in the treatment of cardiovascular disorders in which EDRF deficiency and ROS excess are involved.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
edaravone.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
107.97 kB
Formato
Adobe PDF
|
107.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Manuscript_ed.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
549.75 kB
Formato
Adobe PDF
|
549.75 kB | Adobe PDF | Visualizza/Apri |
|
Supporting_Information_Edaravone.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
503.93 kB
Formato
Adobe PDF
|
503.93 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
